Sarepta Therapeutics, Inc. (SRPT) 10-Year Financial Performance & Capital Metrics

SRPT • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutSarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.Show more

Revenue $1.9B +53.0%
EBITDA $272M +230.2%
Net Income $235M +143.9%
EPS (Diluted) 2.34 +140.3%
Gross Margin 83.22% -5.3%
EBITDA Margin 14.3% +185.1%
Operating Margin 11.47% +153.2%
Net Margin 12.37% +128.7%
ROE 19.71% +122.9%
ROIC 9.1% +164.8%
Debt/Equity 0.88 -45.9%
Interest Coverage 11.86 +197.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 37.9%
✓Trading at only 1.5x book value

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 16.8% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y69.43%

5Y37.94%

3Y39.42%

TTM47.15%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-322.84%

EPS CAGR

10Y-

5Y-

3Y-

TTM-350.43%

ROCE

10Y Avg-35.15%

5Y Avg-13.68%

3Y Avg-7.87%

Latest7.47%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	7.89B	272.13	90.71	473.02%	53.3%	17.48%	1.51%	0.01
BMRNBioMarin Pharmaceutical Inc.	11.09B	57.71	26.11	17.97%	16.82%	8.59%	4.29%	0.11
SRPTSarepta Therapeutics, Inc.	2.22B	21.14	9.03	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.35B	24.37	-3.87	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.87B	17.46	-5.18			-61.26%		0.04
BEAMBeam Therapeutics Inc.	3.42B	33.69	-7.36	-83.18%	-7.44%	-42.92%		0.22
TVTXTravere Therapeutics, Inc.	3.05B	34.10	-8.36	60.55%	-20.32%	-120.36%		6.80
SLNOSoleno Therapeutics, Inc.	2.23B	41.54	-9.48		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.25M	5.42M	154.58M	301.03M	380.83M	540.1M	701.89M	933.01M	1.24B	1.9B
Revenue Growth %	-0.87%	3.33%	27.52%	0.95%	0.27%	0.42%	0.3%	0.33%	0.33%	0.53%
Cost of Goods Sold+	146.19M	130K	7.35M	34.19M	56.59M	63.38M	97.05M	139.99M	150.34M	319.1M
COGS % of Revenue	116.68%	0.02%	0.05%	0.11%	0.15%	0.12%	0.14%	0.15%	0.12%	0.17%
Gross Profit+	-144.94M	5.29M	147.23M	266.84M	324.25M	476.72M	604.84M	793.02M	1.09B	1.58B
Gross Margin %	-115.68%	0.98%	0.95%	0.89%	0.85%	0.88%	0.86%	0.85%	0.88%	0.83%
Gross Profit Growth %	-0.72%	1.04%	26.83%	0.81%	0.22%	0.47%	0.27%	0.31%	0.38%	0.45%
Operating Expenses+	221.44M	272.02M	290.44M	610.47M	1.03B	1.04B	1.06B	1.33B	1.36B	1.36B
OpEx % of Revenue	176.73%	50.18%	1.88%	2.03%	2.7%	1.93%	1.52%	1.42%	1.09%	0.72%
Selling, General & Admin	75.04M	83.75M	122.68M	207.76M	284.81M	317.88M	282.66M	451.42M	481.87M	557.87M
SG&A % of Revenue	59.89%	15.45%	0.79%	0.69%	0.75%	0.59%	0.4%	0.48%	0.39%	0.29%
Research & Development	146.39M	188.27M	166.71M	401.84M	560.91M	722.34M	771.18M	877.09M	877.39M	804.52M
R&D % of Revenue	116.83%	34.73%	1.08%	1.33%	1.47%	1.34%	1.1%	0.94%	0.71%	0.42%
Other Operating Expenses	0	0	1.98M	-656K	184.09M	662K	10.71M	714K	1.56M	2.4M
Operating Income+	-220.18M	-266.73M	-171.64M	-343.63M	-705.56M	-564.16M	-459.71M	-536.2M	-267.82M	218.08M
Operating Margin %	-175.73%	-49.2%	-1.11%	-1.14%	-1.85%	-1.04%	-0.65%	-0.57%	-0.22%	0.11%
Operating Income Growth %	-0.65%	-0.21%	0.36%	-1%	-1.05%	0.2%	0.19%	-0.17%	0.5%	1.81%
EBITDA+	-214.94M	-261.12M	-163.55M	-331.38M	-681.06M	-524.42M	-421.69M	-481.6M	-208.93M	271.97M
EBITDA Margin %	-171.54%	-48.17%	-1.06%	-1.1%	-1.79%	-0.97%	-0.6%	-0.52%	-0.17%	0.14%
EBITDA Growth %	-0.65%	-0.21%	0.37%	-1.03%	-1.06%	0.23%	0.2%	-0.14%	0.57%	2.3%
D&A (Non-Cash Add-back)	5.25M	5.61M	8.09M	12.24M	24.5M	39.74M	38.02M	54.6M	58.89M	53.89M
EBIT	-218.66M	-266.73M	-42.83M	-328.9M	-683.21M	-493.12M	-355.42M	-636.72M	-498.09M	279.17M
Net Interest Income+	-475K	-1.39M	-3.99M	-26.9M	-23.43M	-56.98M	-63.01M	-25.52M	63.96M	53.38M
Interest Income	890K	507K	1.81M	6.81M	7.24M	2.97M	511K	27.72M	85.97M	71.77M
Interest Expense	1.36M	1.89M	5.78M	33.71M	30.67M	59.95M	63.52M	53.25M	22.01M	18.39M
Other Income/Expense	154K	-535K	123.01M	-18.98M	-8.32M	11.1M	40.76M	-153.76M	-252.27M	42.69M
Pretax Income+	-220.03M	-267.26M	-48.63M	-362.61M	-713.88M	-553.07M	-418.95M	-689.96M	-520.1M	260.77M
Pretax Margin %	-175.6%	-49.3%	-0.31%	-1.2%	-1.87%	-1.02%	-0.6%	-0.74%	-0.42%	0.14%
Income Tax+	0	0	2.06M	-692K	1.2M	1.06M	-168K	13.53M	15.88M	25.54M
Effective Tax Rate %	1%	1%	1.04%	1%	1%	1%	1%	1.02%	1.03%	0.9%
Net Income+	-220.03M	-267.26M	-50.69M	-361.92M	-715.08M	-554.13M	-418.78M	-703.49M	-535.98M	235.24M
Net Margin %	-175.6%	-49.3%	-0.33%	-1.2%	-1.88%	-1.03%	-0.6%	-0.75%	-0.43%	0.12%
Net Income Growth %	-0.62%	-0.21%	0.81%	-6.14%	-0.98%	0.23%	0.24%	-0.68%	0.24%	1.44%
Net Income (Continuing)	-220.03M	-267.26M	-50.69M	-361.92M	-715.08M	-554.13M	-418.78M	-703.49M	-535.98M	235.24M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-5.20	-5.49	-0.86	-5.46	-9.71	-7.11	-5.15	-8.03	-5.80	2.34
EPS Growth %	-0.53%	-0.06%	0.84%	-5.35%	-0.78%	0.27%	0.28%	-0.56%	0.28%	1.4%
EPS (Basic)	-5.20	-5.49	-0.86	-5.46	-9.71	-7.11	-5.15	-8.03	-5.80	2.47
Diluted Shares Outstanding	42.29M	48.7M	58.82M	66.25M	73.61M	77.96M	81.26M	87.56M	92.4M	107.88M
Basic Shares Outstanding	42.29M	48.68M	58.82M	66.25M	73.61M	77.96M	81.26M	87.56M	92.4M	95.08M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	224.54M	373.48M	1.23B	1.43B	1.47B	2.49B	2.6B	2.56B	2.58B	3.07B
Cash & Short-Term Investments	192.49M	317.85M	1.08B	1.17B	1.12B	1.94B	2.12B	1.99B	1.68B	1.35B
Cash Only	80.3M	122.42M	599.69M	370.83M	835.08M	1.5B	2.12B	966.78M	428.43M	1.1B
Short-Term Investments	112.19M	195.43M	479.37M	803.08M	289.67M	435.92M	0	1.02B	1.25B	251.78M
Accounts Receivable	3.98M	5.23M	29.47M	49.04M	93.94M	138.58M	172.75M	261.6M	436.98M	649.73M
Days Sales Outstanding	1.16K	352.01	69.58	59.47	90.03	93.65	89.83	102.34	128.28	124.69
Inventory	26.87M	12.81M	83.61M	125.44M	171.38M	231.96M	186.21M	203.97M	322.86M	749.96M
Days Inventory Outstanding	67.1	35.97K	4.15K	1.34K	1.11K	1.34K	700.34	531.82	783.83	857.84
Other Current Assets	24.97M	35.21M	22.41M	62.14M	59.52M	138.5M	5.3M	6.82M	12.48M	9.21M
Total Non-Current Assets+	49.24M	50.63M	79.32M	215.89M	353.91M	499.52M	543.88M	570.5M	685.25M	889.71M
Property, Plant & Equipment	37.34M	37.8M	43.16M	97.02M	167.55M	282.19M	236.69M	244.99M	357.11M	488.65M
Fixed Asset Turnover	0.03x	0.14x	3.58x	3.10x	2.27x	1.91x	2.97x	3.81x	3.48x	3.89x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	6.64M	8.08M	14.36M	11.57M	12.5M	13.63M	14.24M	7.58M	29.62M	26.89M
Long-Term Investments	783K	0	9.98M	107.29M	41.5M	48.11M	34.89M	31.32M	6.53M	136.87M
Other Non-Current Assets	5.25M	4.75M	21.81M	107.29M	132.36M	155.59M	258.06M	286.62M	291.99M	237.3M
Total Assets+	273.78M	424.1M	1.31B	1.64B	1.82B	2.98B	3.15B	3.13B	3.26B	3.96B
Asset Turnover	0.00x	0.01x	0.12x	0.18x	0.21x	0.18x	0.22x	0.30x	0.38x	0.48x
Asset Growth %	-0.07%	0.55%	2.08%	0.26%	0.11%	0.64%	0.05%	-0.01%	0.04%	0.21%
Total Current Liabilities+	62.29M	75.42M	88.33M	173.69M	264.77M	416.03M	452.73M	619.6M	653.66M	731.68M
Accounts Payable	20.23M	29.69M	8.47M	33.83M	68.09M	111.09M	76.74M	95.88M	164.92M	214.44M
Days Payables Outstanding	50.52	83.36K	420.3	361.11	439.23	639.74	288.62	249.98	400.38	245.29
Short-Term Debt	8.43M	10.11M	6.17M	0	7.85M	20.93M	0	0	105.48M	0
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	0	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	22.14M	23.57M	55.03M	111.56M	145.59M	143.96M	110.44M	134.73M	178.81M	200.28M
Current Ratio	3.60x	4.95x	13.91x	8.21x	5.55x	5.97x	5.75x	4.13x	3.95x	4.20x
Quick Ratio	3.17x	4.78x	12.96x	7.49x	4.90x	5.42x	5.34x	3.80x	3.45x	3.18x
Cash Conversion Cycle	1.18K	-47.03K	3.8K	1.04K	756.26	789.72	501.55	384.18	511.73	737.24
Total Non-Current Liabilities+	21.14M	11.99M	430.42M	436.11M	739.87M	1.81B	1.77B	2.12B	1.75B	1.7B
Long-Term Debt	14.97M	6.04M	424.88M	420.55M	681.9M	992.49M	1.1B	1.54B	1.13B	1.14B
Capital Lease Obligations	0	0	0	0	47.72M	80.37M	41.51M	57.58M	140.97M	192.47M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	6.17M	5.95M	5.54M	15.55M	10.25M	70.58M	54.6M	36.94M	41.1M	49.15M
Total Liabilities	83.44M	87.41M	518.75M	609.8M	1B	2.22B	2.22B	2.74B	2.41B	2.44B
Total Debt+	23.4M	16.15M	431.05M	420.55M	737.47M	1.09B	1.15B	1.62B	1.4B	1.34B
Net Debt	-56.91M	-106.27M	-168.64M	49.73M	-97.61M	-408.86M	-962.43M	650.58M	968.38M	240.06M
Debt / Equity	0.12x	0.05x	0.55x	0.41x	0.90x	1.44x	1.24x	4.20x	1.63x	0.88x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	4.94x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	0.88x
Interest Coverage	-161.31x	-140.98x	-29.69x	-10.19x	-23.01x	-9.41x	-7.24x	-10.07x	-12.17x	11.86x
Total Equity+	190.35M	336.69M	789.22M	1.03B	818.19M	761.76M	928.01M	384.95M	859.34M	1.53B
Equity Growth %	-0.23%	0.77%	1.34%	0.31%	-0.21%	-0.07%	0.22%	-0.59%	1.23%	0.78%
Book Value per Share	4.50	6.91	13.42	15.58	11.11	9.77	11.42	4.40	9.30	14.16
Total Shareholders' Equity	190.35M	336.69M	789.22M	1.03B	818.19M	761.76M	928.01M	384.95M	859.34M	1.53B
Common Stock	5K	5K	6K	7K	8K	8K	9K	9K	9K	10K
Retained Earnings	-899.05M	-1.17B	-1.22B	-1.58B	-2.29B	-2.85B	-3.21B	-3.91B	-4.45B	-4.21B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-111K	-120K	-379K	-99K	50K	3K	-20K	-1.66M	918K	-218K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-149.47M	-245.82M	-232M	-388.66M	-456.46M	107.47M	-443.17M	-325.35M	-500.99M	-205.79M
Operating CF Margin %	-119.29%	-45.35%	-1.5%	-1.29%	-1.2%	0.2%	-0.63%	-0.35%	-0.4%	-0.11%
Operating CF Growth %	-0.16%	-0.64%	0.06%	-0.68%	-0.17%	1.24%	-5.12%	0.27%	-0.54%	0.59%
Net Income	-220.03M	-267.26M	-50.69M	-361.92M	-715.08M	-554.13M	-418.78M	-703.49M	-535.98M	235.24M
Depreciation & Amortization	5.25M	5.61M	8.09M	12.24M	24.5M	26.91M	38.02M	41.86M	44.4M	37.72M
Stock-Based Compensation	32.12M	29.96M	30.46M	50.13M	78.6M	108.07M	113.94M	233.02M	182.51M	184.3M
Deferred Taxes	849K	373K	-83K	-1.41M	0	10.64M	15.81M	0	0	0
Other Non-Cash Items	367K	1.27M	-122.32M	20.19M	222.39M	-38.09M	-94M	142.73M	289.16M	53.56M
Working Capital Changes	31.98M	-15.77M	-97.46M	-107.89M	-66.88M	554.06M	-98.17M	-39.47M	-481.09M	-716.61M
Change in Receivables	-1.56M	-1.25M	-24.24M	-19.58M	-41.84M	-10.46M	-51.65M	-61.64M	-185.7M	-201.66M
Change in Inventory	-147M	-12.81M	-70.79M	-41.84M	-45.93M	-60.58M	-83.77M	-50.78M	-147.71M	-395.17M
Change in Payables	18.3M	7.31M	12.93M	90.16M	122.98M	42M	23.3M	147.57M	-50.13M	110.65M
Cash from Investing+	8.41M	-90.19M	-178.81M	-370.49M	286.73M	-121.72M	495.41M	-1.05B	-165.8M	755.56M
Capital Expenditures	-4.83M	-6.87M	-21.21M	-64.34M	-59.63M	-82.2M	-38.49M	-30.82M	-76.11M	-136.96M
CapEx % of Revenue	3.86%	1.27%	0.14%	0.21%	0.16%	0.15%	0.05%	0.03%	0.06%	0.07%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-1.43M	-1.52M	134.22M	-3.19M	-3.08M	104.57M	97.89M	-1.43M	90.76M	-10M
Cash from Financing+	147.81M	378.13M	888.08M	530.15M	642.55M	682.32M	561.57M	232.51M	125M	124.81M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	10.49M	20.93M	-50.83M	563.63M	31.57M	79.12M	13.04M	-71.66M	125M	45.35M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-154.3M	-252.69M	-253.21M	-453M	-516.09M	25.26M	-481.66M	-357.6M	-588.34M	-342.74M
FCF Margin %	-123.14%	-46.61%	-1.64%	-1.5%	-1.36%	0.05%	-0.69%	-0.38%	-0.47%	-0.18%
FCF Growth %	0.01%	-0.64%	-0%	-0.79%	-0.14%	1.05%	-20.07%	0.26%	-0.65%	0.42%
FCF per Share	-3.65	-5.19	-4.30	-6.84	-7.01	0.32	-5.93	-4.08	-6.37	-3.18
FCF Conversion (FCF/Net Income)	0.68x	0.92x	4.58x	1.07x	0.64x	-0.19x	1.06x	0.46x	0.93x	-0.87x
Interest Paid	0	0	1.91M	11.31M	8.55M	34.42M	55.95M	44.42M	15.92M	15.86M
Taxes Paid	0	0	5.34M	1.55M	933K	2.51M	583K	1.7M	15.08M	22.59M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-100.47%	-101.42%	-9%	-39.74%	-77.29%	-70.15%	-49.57%	-107.16%	-86.15%	19.71%
Return on Invested Capital (ROIC)	-105.23%	-109.96%	-30.25%	-30.27%	-58.71%	-78.83%	-216.52%	-80.34%	-14.03%	9.1%
Gross Margin	-11567.52%	97.6%	95.24%	88.64%	85.14%	88.26%	86.17%	85%	87.91%	83.22%
Net Margin	-17560.26%	-4930.18%	-32.79%	-120.23%	-187.77%	-102.6%	-59.66%	-75.4%	-43.11%	12.37%
Debt / Equity	0.12x	0.05x	0.55x	0.41x	0.90x	1.44x	1.24x	4.20x	1.63x	0.88x
Interest Coverage	-161.31x	-140.98x	-29.69x	-10.19x	-23.01x	-9.41x	-7.24x	-10.07x	-12.17x	11.86x
FCF Conversion	0.68x	0.92x	4.58x	1.07x	0.64x	-0.19x	1.06x	0.46x	0.93x	-0.87x
Revenue Growth	-87.16%	332.64%	2751.58%	94.74%	26.51%	41.82%	29.96%	32.93%	33.26%	52.97%

Revenue by Geography

	2022	2023	2024
UNITED STATES	747.1M	797.94M	820.79M
UNITED STATES Growth	-	6.81%	2.86%
World	-	146.58M	150.25M
World Growth	-	-	2.51%
Non-US	96.7M	-	-
Non-US Growth	-	-	-

Frequently Asked Questions

Valuation & Price

Sarepta Therapeutics, Inc. (SRPT) has a price-to-earnings (P/E) ratio of 9.0x. This may indicate the stock is undervalued or faces growth challenges.

Growth & Financials

Sarepta Therapeutics, Inc. (SRPT) reported $2.41B in revenue for fiscal year 2024. This represents a 5037% increase from $47.0M in 2011.

Sarepta Therapeutics, Inc. (SRPT) grew revenue by 53.0% over the past year. This is strong growth.

Sarepta Therapeutics, Inc. (SRPT) reported a net loss of $271.5M for fiscal year 2024.

Dividend & Returns

Sarepta Therapeutics, Inc. (SRPT) has a return on equity (ROE) of 19.7%. This is reasonable for most industries.

Sarepta Therapeutics, Inc. (SRPT) had negative free cash flow of $343.6M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Sarepta Therapeutics, Inc. (SRPT) 10-Year Financial Performance & Capital Metrics

SRPT • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

Revenue $1.9B +53.0%
EBITDA $272M +230.2%
Net Income $235M +143.9%
EPS (Diluted) 2.34 +140.3%
Gross Margin 83.22% -5.3%
EBITDA Margin 14.3% +185.1%
Operating Margin 11.47% +153.2%
Net Margin 12.37% +128.7%
ROE 19.71% +122.9%
ROIC 9.1% +164.8%
Debt/Equity 0.88 -45.9%
Interest Coverage 11.86 +197.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 37.9%
✓Trading at only 1.5x book value

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 16.8% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y69.43%

5Y37.94%

3Y39.42%

TTM47.15%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-322.84%

EPS CAGR

10Y-

5Y-

3Y-

TTM-350.43%

ROCE

10Y Avg-35.15%

5Y Avg-13.68%

3Y Avg-7.87%

Latest7.47%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	7.89B	272.13	90.71	473.02%	53.3%	17.48%	1.51%	0.01
BMRNBioMarin Pharmaceutical Inc.	11.09B	57.71	26.11	17.97%	16.82%	8.59%	4.29%	0.11
SRPTSarepta Therapeutics, Inc.	2.22B	21.14	9.03	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.35B	24.37	-3.87	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.87B	17.46	-5.18			-61.26%		0.04
BEAMBeam Therapeutics Inc.	3.42B	33.69	-7.36	-83.18%	-7.44%	-42.92%		0.22
TVTXTravere Therapeutics, Inc.	3.05B	34.10	-8.36	60.55%	-20.32%	-120.36%		6.80
SLNOSoleno Therapeutics, Inc.	2.23B	41.54	-9.48		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.25M	5.42M	154.58M	301.03M	380.83M	540.1M	701.89M	933.01M	1.24B	1.9B
Revenue Growth %	-0.87%	3.33%	27.52%	0.95%	0.27%	0.42%	0.3%	0.33%	0.33%	0.53%
Cost of Goods Sold+	146.19M	130K	7.35M	34.19M	56.59M	63.38M	97.05M	139.99M	150.34M	319.1M
COGS % of Revenue	116.68%	0.02%	0.05%	0.11%	0.15%	0.12%	0.14%	0.15%	0.12%	0.17%
Gross Profit+	-144.94M	5.29M	147.23M	266.84M	324.25M	476.72M	604.84M	793.02M	1.09B	1.58B
Gross Margin %	-115.68%	0.98%	0.95%	0.89%	0.85%	0.88%	0.86%	0.85%	0.88%	0.83%
Gross Profit Growth %	-0.72%	1.04%	26.83%	0.81%	0.22%	0.47%	0.27%	0.31%	0.38%	0.45%
Operating Expenses+	221.44M	272.02M	290.44M	610.47M	1.03B	1.04B	1.06B	1.33B	1.36B	1.36B
OpEx % of Revenue	176.73%	50.18%	1.88%	2.03%	2.7%	1.93%	1.52%	1.42%	1.09%	0.72%
Selling, General & Admin	75.04M	83.75M	122.68M	207.76M	284.81M	317.88M	282.66M	451.42M	481.87M	557.87M
SG&A % of Revenue	59.89%	15.45%	0.79%	0.69%	0.75%	0.59%	0.4%	0.48%	0.39%	0.29%
Research & Development	146.39M	188.27M	166.71M	401.84M	560.91M	722.34M	771.18M	877.09M	877.39M	804.52M
R&D % of Revenue	116.83%	34.73%	1.08%	1.33%	1.47%	1.34%	1.1%	0.94%	0.71%	0.42%
Other Operating Expenses	0	0	1.98M	-656K	184.09M	662K	10.71M	714K	1.56M	2.4M
Operating Income+	-220.18M	-266.73M	-171.64M	-343.63M	-705.56M	-564.16M	-459.71M	-536.2M	-267.82M	218.08M
Operating Margin %	-175.73%	-49.2%	-1.11%	-1.14%	-1.85%	-1.04%	-0.65%	-0.57%	-0.22%	0.11%
Operating Income Growth %	-0.65%	-0.21%	0.36%	-1%	-1.05%	0.2%	0.19%	-0.17%	0.5%	1.81%
EBITDA+	-214.94M	-261.12M	-163.55M	-331.38M	-681.06M	-524.42M	-421.69M	-481.6M	-208.93M	271.97M
EBITDA Margin %	-171.54%	-48.17%	-1.06%	-1.1%	-1.79%	-0.97%	-0.6%	-0.52%	-0.17%	0.14%
EBITDA Growth %	-0.65%	-0.21%	0.37%	-1.03%	-1.06%	0.23%	0.2%	-0.14%	0.57%	2.3%
D&A (Non-Cash Add-back)	5.25M	5.61M	8.09M	12.24M	24.5M	39.74M	38.02M	54.6M	58.89M	53.89M
EBIT	-218.66M	-266.73M	-42.83M	-328.9M	-683.21M	-493.12M	-355.42M	-636.72M	-498.09M	279.17M
Net Interest Income+	-475K	-1.39M	-3.99M	-26.9M	-23.43M	-56.98M	-63.01M	-25.52M	63.96M	53.38M
Interest Income	890K	507K	1.81M	6.81M	7.24M	2.97M	511K	27.72M	85.97M	71.77M
Interest Expense	1.36M	1.89M	5.78M	33.71M	30.67M	59.95M	63.52M	53.25M	22.01M	18.39M
Other Income/Expense	154K	-535K	123.01M	-18.98M	-8.32M	11.1M	40.76M	-153.76M	-252.27M	42.69M
Pretax Income+	-220.03M	-267.26M	-48.63M	-362.61M	-713.88M	-553.07M	-418.95M	-689.96M	-520.1M	260.77M
Pretax Margin %	-175.6%	-49.3%	-0.31%	-1.2%	-1.87%	-1.02%	-0.6%	-0.74%	-0.42%	0.14%
Income Tax+	0	0	2.06M	-692K	1.2M	1.06M	-168K	13.53M	15.88M	25.54M
Effective Tax Rate %	1%	1%	1.04%	1%	1%	1%	1%	1.02%	1.03%	0.9%
Net Income+	-220.03M	-267.26M	-50.69M	-361.92M	-715.08M	-554.13M	-418.78M	-703.49M	-535.98M	235.24M
Net Margin %	-175.6%	-49.3%	-0.33%	-1.2%	-1.88%	-1.03%	-0.6%	-0.75%	-0.43%	0.12%
Net Income Growth %	-0.62%	-0.21%	0.81%	-6.14%	-0.98%	0.23%	0.24%	-0.68%	0.24%	1.44%
Net Income (Continuing)	-220.03M	-267.26M	-50.69M	-361.92M	-715.08M	-554.13M	-418.78M	-703.49M	-535.98M	235.24M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-5.20	-5.49	-0.86	-5.46	-9.71	-7.11	-5.15	-8.03	-5.80	2.34
EPS Growth %	-0.53%	-0.06%	0.84%	-5.35%	-0.78%	0.27%	0.28%	-0.56%	0.28%	1.4%
EPS (Basic)	-5.20	-5.49	-0.86	-5.46	-9.71	-7.11	-5.15	-8.03	-5.80	2.47
Diluted Shares Outstanding	42.29M	48.7M	58.82M	66.25M	73.61M	77.96M	81.26M	87.56M	92.4M	107.88M
Basic Shares Outstanding	42.29M	48.68M	58.82M	66.25M	73.61M	77.96M	81.26M	87.56M	92.4M	95.08M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	224.54M	373.48M	1.23B	1.43B	1.47B	2.49B	2.6B	2.56B	2.58B	3.07B
Cash & Short-Term Investments	192.49M	317.85M	1.08B	1.17B	1.12B	1.94B	2.12B	1.99B	1.68B	1.35B
Cash Only	80.3M	122.42M	599.69M	370.83M	835.08M	1.5B	2.12B	966.78M	428.43M	1.1B
Short-Term Investments	112.19M	195.43M	479.37M	803.08M	289.67M	435.92M	0	1.02B	1.25B	251.78M
Accounts Receivable	3.98M	5.23M	29.47M	49.04M	93.94M	138.58M	172.75M	261.6M	436.98M	649.73M
Days Sales Outstanding	1.16K	352.01	69.58	59.47	90.03	93.65	89.83	102.34	128.28	124.69
Inventory	26.87M	12.81M	83.61M	125.44M	171.38M	231.96M	186.21M	203.97M	322.86M	749.96M
Days Inventory Outstanding	67.1	35.97K	4.15K	1.34K	1.11K	1.34K	700.34	531.82	783.83	857.84
Other Current Assets	24.97M	35.21M	22.41M	62.14M	59.52M	138.5M	5.3M	6.82M	12.48M	9.21M
Total Non-Current Assets+	49.24M	50.63M	79.32M	215.89M	353.91M	499.52M	543.88M	570.5M	685.25M	889.71M
Property, Plant & Equipment	37.34M	37.8M	43.16M	97.02M	167.55M	282.19M	236.69M	244.99M	357.11M	488.65M
Fixed Asset Turnover	0.03x	0.14x	3.58x	3.10x	2.27x	1.91x	2.97x	3.81x	3.48x	3.89x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	6.64M	8.08M	14.36M	11.57M	12.5M	13.63M	14.24M	7.58M	29.62M	26.89M
Long-Term Investments	783K	0	9.98M	107.29M	41.5M	48.11M	34.89M	31.32M	6.53M	136.87M
Other Non-Current Assets	5.25M	4.75M	21.81M	107.29M	132.36M	155.59M	258.06M	286.62M	291.99M	237.3M
Total Assets+	273.78M	424.1M	1.31B	1.64B	1.82B	2.98B	3.15B	3.13B	3.26B	3.96B
Asset Turnover	0.00x	0.01x	0.12x	0.18x	0.21x	0.18x	0.22x	0.30x	0.38x	0.48x
Asset Growth %	-0.07%	0.55%	2.08%	0.26%	0.11%	0.64%	0.05%	-0.01%	0.04%	0.21%
Total Current Liabilities+	62.29M	75.42M	88.33M	173.69M	264.77M	416.03M	452.73M	619.6M	653.66M	731.68M
Accounts Payable	20.23M	29.69M	8.47M	33.83M	68.09M	111.09M	76.74M	95.88M	164.92M	214.44M
Days Payables Outstanding	50.52	83.36K	420.3	361.11	439.23	639.74	288.62	249.98	400.38	245.29
Short-Term Debt	8.43M	10.11M	6.17M	0	7.85M	20.93M	0	0	105.48M	0
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	0	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	22.14M	23.57M	55.03M	111.56M	145.59M	143.96M	110.44M	134.73M	178.81M	200.28M
Current Ratio	3.60x	4.95x	13.91x	8.21x	5.55x	5.97x	5.75x	4.13x	3.95x	4.20x
Quick Ratio	3.17x	4.78x	12.96x	7.49x	4.90x	5.42x	5.34x	3.80x	3.45x	3.18x
Cash Conversion Cycle	1.18K	-47.03K	3.8K	1.04K	756.26	789.72	501.55	384.18	511.73	737.24
Total Non-Current Liabilities+	21.14M	11.99M	430.42M	436.11M	739.87M	1.81B	1.77B	2.12B	1.75B	1.7B
Long-Term Debt	14.97M	6.04M	424.88M	420.55M	681.9M	992.49M	1.1B	1.54B	1.13B	1.14B
Capital Lease Obligations	0	0	0	0	47.72M	80.37M	41.51M	57.58M	140.97M	192.47M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	6.17M	5.95M	5.54M	15.55M	10.25M	70.58M	54.6M	36.94M	41.1M	49.15M
Total Liabilities	83.44M	87.41M	518.75M	609.8M	1B	2.22B	2.22B	2.74B	2.41B	2.44B
Total Debt+	23.4M	16.15M	431.05M	420.55M	737.47M	1.09B	1.15B	1.62B	1.4B	1.34B
Net Debt	-56.91M	-106.27M	-168.64M	49.73M	-97.61M	-408.86M	-962.43M	650.58M	968.38M	240.06M
Debt / Equity	0.12x	0.05x	0.55x	0.41x	0.90x	1.44x	1.24x	4.20x	1.63x	0.88x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	4.94x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	0.88x
Interest Coverage	-161.31x	-140.98x	-29.69x	-10.19x	-23.01x	-9.41x	-7.24x	-10.07x	-12.17x	11.86x
Total Equity+	190.35M	336.69M	789.22M	1.03B	818.19M	761.76M	928.01M	384.95M	859.34M	1.53B
Equity Growth %	-0.23%	0.77%	1.34%	0.31%	-0.21%	-0.07%	0.22%	-0.59%	1.23%	0.78%
Book Value per Share	4.50	6.91	13.42	15.58	11.11	9.77	11.42	4.40	9.30	14.16
Total Shareholders' Equity	190.35M	336.69M	789.22M	1.03B	818.19M	761.76M	928.01M	384.95M	859.34M	1.53B
Common Stock	5K	5K	6K	7K	8K	8K	9K	9K	9K	10K
Retained Earnings	-899.05M	-1.17B	-1.22B	-1.58B	-2.29B	-2.85B	-3.21B	-3.91B	-4.45B	-4.21B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-111K	-120K	-379K	-99K	50K	3K	-20K	-1.66M	918K	-218K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-149.47M	-245.82M	-232M	-388.66M	-456.46M	107.47M	-443.17M	-325.35M	-500.99M	-205.79M
Operating CF Margin %	-119.29%	-45.35%	-1.5%	-1.29%	-1.2%	0.2%	-0.63%	-0.35%	-0.4%	-0.11%
Operating CF Growth %	-0.16%	-0.64%	0.06%	-0.68%	-0.17%	1.24%	-5.12%	0.27%	-0.54%	0.59%
Net Income	-220.03M	-267.26M	-50.69M	-361.92M	-715.08M	-554.13M	-418.78M	-703.49M	-535.98M	235.24M
Depreciation & Amortization	5.25M	5.61M	8.09M	12.24M	24.5M	26.91M	38.02M	41.86M	44.4M	37.72M
Stock-Based Compensation	32.12M	29.96M	30.46M	50.13M	78.6M	108.07M	113.94M	233.02M	182.51M	184.3M
Deferred Taxes	849K	373K	-83K	-1.41M	0	10.64M	15.81M	0	0	0
Other Non-Cash Items	367K	1.27M	-122.32M	20.19M	222.39M	-38.09M	-94M	142.73M	289.16M	53.56M
Working Capital Changes	31.98M	-15.77M	-97.46M	-107.89M	-66.88M	554.06M	-98.17M	-39.47M	-481.09M	-716.61M
Change in Receivables	-1.56M	-1.25M	-24.24M	-19.58M	-41.84M	-10.46M	-51.65M	-61.64M	-185.7M	-201.66M
Change in Inventory	-147M	-12.81M	-70.79M	-41.84M	-45.93M	-60.58M	-83.77M	-50.78M	-147.71M	-395.17M
Change in Payables	18.3M	7.31M	12.93M	90.16M	122.98M	42M	23.3M	147.57M	-50.13M	110.65M
Cash from Investing+	8.41M	-90.19M	-178.81M	-370.49M	286.73M	-121.72M	495.41M	-1.05B	-165.8M	755.56M
Capital Expenditures	-4.83M	-6.87M	-21.21M	-64.34M	-59.63M	-82.2M	-38.49M	-30.82M	-76.11M	-136.96M
CapEx % of Revenue	3.86%	1.27%	0.14%	0.21%	0.16%	0.15%	0.05%	0.03%	0.06%	0.07%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-1.43M	-1.52M	134.22M	-3.19M	-3.08M	104.57M	97.89M	-1.43M	90.76M	-10M
Cash from Financing+	147.81M	378.13M	888.08M	530.15M	642.55M	682.32M	561.57M	232.51M	125M	124.81M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	10.49M	20.93M	-50.83M	563.63M	31.57M	79.12M	13.04M	-71.66M	125M	45.35M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-154.3M	-252.69M	-253.21M	-453M	-516.09M	25.26M	-481.66M	-357.6M	-588.34M	-342.74M
FCF Margin %	-123.14%	-46.61%	-1.64%	-1.5%	-1.36%	0.05%	-0.69%	-0.38%	-0.47%	-0.18%
FCF Growth %	0.01%	-0.64%	-0%	-0.79%	-0.14%	1.05%	-20.07%	0.26%	-0.65%	0.42%
FCF per Share	-3.65	-5.19	-4.30	-6.84	-7.01	0.32	-5.93	-4.08	-6.37	-3.18
FCF Conversion (FCF/Net Income)	0.68x	0.92x	4.58x	1.07x	0.64x	-0.19x	1.06x	0.46x	0.93x	-0.87x
Interest Paid	0	0	1.91M	11.31M	8.55M	34.42M	55.95M	44.42M	15.92M	15.86M
Taxes Paid	0	0	5.34M	1.55M	933K	2.51M	583K	1.7M	15.08M	22.59M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-100.47%	-101.42%	-9%	-39.74%	-77.29%	-70.15%	-49.57%	-107.16%	-86.15%	19.71%
Return on Invested Capital (ROIC)	-105.23%	-109.96%	-30.25%	-30.27%	-58.71%	-78.83%	-216.52%	-80.34%	-14.03%	9.1%
Gross Margin	-11567.52%	97.6%	95.24%	88.64%	85.14%	88.26%	86.17%	85%	87.91%	83.22%
Net Margin	-17560.26%	-4930.18%	-32.79%	-120.23%	-187.77%	-102.6%	-59.66%	-75.4%	-43.11%	12.37%
Debt / Equity	0.12x	0.05x	0.55x	0.41x	0.90x	1.44x	1.24x	4.20x	1.63x	0.88x
Interest Coverage	-161.31x	-140.98x	-29.69x	-10.19x	-23.01x	-9.41x	-7.24x	-10.07x	-12.17x	11.86x
FCF Conversion	0.68x	0.92x	4.58x	1.07x	0.64x	-0.19x	1.06x	0.46x	0.93x	-0.87x
Revenue Growth	-87.16%	332.64%	2751.58%	94.74%	26.51%	41.82%	29.96%	32.93%	33.26%	52.97%

Revenue by Geography

	2022	2023	2024
UNITED STATES	747.1M	797.94M	820.79M
UNITED STATES Growth	-	6.81%	2.86%
World	-	146.58M	150.25M
World Growth	-	-	2.51%
Non-US	96.7M	-	-
Non-US Growth	-	-	-

Frequently Asked Questions

Valuation & Price

Sarepta Therapeutics, Inc. (SRPT) has a price-to-earnings (P/E) ratio of 9.0x. This may indicate the stock is undervalued or faces growth challenges.

Growth & Financials

Sarepta Therapeutics, Inc. (SRPT) reported $2.41B in revenue for fiscal year 2024. This represents a 5037% increase from $47.0M in 2011.

Sarepta Therapeutics, Inc. (SRPT) grew revenue by 53.0% over the past year. This is strong growth.

Sarepta Therapeutics, Inc. (SRPT) reported a net loss of $271.5M for fiscal year 2024.

Dividend & Returns

Sarepta Therapeutics, Inc. (SRPT) has a return on equity (ROE) of 19.7%. This is reasonable for most industries.

Sarepta Therapeutics, Inc. (SRPT) had negative free cash flow of $343.6M in fiscal year 2024, likely due to heavy capital investments.